| 06.24.24 | Novo takes next step in GLP-1 arms race w ith $4.1B plant outlay; Biopharma’s smartest M&A deals

Klicken Sie hier, um Fiercebiotech.com zu abonnieren

Laden...

5 Monate vor

Html
Text

PM Tracker

Shape Your Molecule's Development Journey

Create an optimal path to the clinic that best suits your molecule and critical milestones. We now offer a full suite of integrated drug substance/drug product DNA-to-IND programs to accelerate any molecule type to the clinic. Download our white papers to learn more about our tailored CMC strategies.

Today’s Big News

Jun 24, 2024

Novo Nordisk reveals plan to build mammoth $4.1B plant in NC to help produce Ozempic, Wegovy

ADA: Continuous glucose monitors, smart insulin pumps make their case for Type 2 diabetes

Top 10 smartest deals in biopharma

Alnylam CEO touts ‘big-win scenario’ for Amvuttra in closely watched heart disease trial

Antibiotics specialist Xellia plots 247 layoffs on the heels of Ohio plant sale to Hikma

Altimmune touts 'best-in-class' lean mass results for weight loss therapy in quest to outdo big time competitors

Fierce Clinical Summit

September 25-27, 2024 | Philadelphia, PA

Join the Fierce Clinical Summit, the premier event for clinical research and trial management. Explore topics in Clinical Operations, Quality, and DCT & Technology. Learn, network, and connect with peers to advance industry standards and innovations in clinical trials. Save $500 with Early Bird Rate Today!

Featured

Novo Nordisk reveals plan to build mammoth $4.1B plant in NC to help produce Ozempic, Wegovy

By Kevin Dunleavy

A month after Eli Lilly revealed a $5.3 billion investment to increase its manufacturing capacity of its diabetes and obesity treatments, Novo Nordisk has answered. The Danish drugmaker said it will spend $4.1 billion to construct a second fill-finish plant at its sprawling campus in Clayton, North Carolina.

ADA: Continuous glucose monitors, smart insulin pumps make their case for Type 2 diabetes

By Conor Hale

At the scientific sessions of the American Diabetes Association, Insulet, Dexcom and more illustrated the benefits that technologies can bring to the millions of people in the U.S. with Type 2 diabetes.

Top 10 smartest deals in biopharma

By James Waldron

The past couple of years have seen Big Pharmas whip out their wallets to place high-stake bets in the red-hot races for antibody-drug conjugates, radiopharmaceuticals and obesity drugs, to name a few. We wanted to take another look at some of the deals that have kept our attention.

Alnylam CEO touts 'big-win scenario' for Amvuttra in closely watched heart disease trial

By Angus Liu

In one of the most closely watched biotech trial readouts of the year, Alnylam Pharmaceuticals said its RNA interference drug reduced the risk of death or recurrent cardiovascular events. The result appears to be a best-case scenario for Alnylam, but analysts are still eager to see detailed data from Amvuttra's combination with Pfizer's tafamidis.

Whitepaper: The Emergence of Multi-modal Real-world Data

Achieving complete and informed drug discovery and clinical development requires the right mix of clinical, claims and other real-world data (RWD). Access this insightful resource to learn how to do just that. Download now.

Antibiotics specialist Xellia plots 247 layoffs on the heels of Ohio plant sale to Hikma

By Fraiser Kansteiner

In connection with the sale of the company’s Bedford plant on the outskirts of Cleveland, Ohio, to Hikma, Xellia said it’s cutting 247 positions in the U.S. Of the affected staffers, 214 work at the Bedford facility, Xellia said in a Worker Adjustment and Retraining Notification alert sent to the state.

Altimmune touts 'best-in-class' lean mass results for weight loss therapy in quest to outdo big time competitors

By Annalee Armstrong

After a full data analysis, Altimmune is heralding phase 2 obesity data for pemvidutide as “best-in-class” for spurring weight loss while preserving lean mass.

Amylyx seeks to fill Relyvrio-sized hole in pipeline with $35M GLP-1 buy

By Annalee Armstrong

Searching for a path forward after the withdrawal of Relyvrio in amyotrophic lateral sclerosis, Amylyx Pharmaceuticals has purchased a GLP-1 receptor antagonist from Eiger Biopharma for $35.1 million.

Argenx's Vyvgart Hytrulo snares 2nd US nod as FDA gives green light in autoimmune disease CIDP

By Fraiser Kansteiner

Argenx's Vyvgart has won approval to treat its second indication in the U.S. and its third globally as the U.S. FDA cleared the med to treat the rare and debilitating peripheral nervous system disease chronic inflammatory demyelinating polyneuropathy (CIDP).

Fierce podcasts

Don’t miss an episode

A look at 'friend-shoring' and the drug shortage challenge

In this week’s episode of “The Top Line,” Fierce Pharma’s Zoey Becker sits down with Bobby Sheng, the CEO of Bora Pharmaceuticals, to discuss the concept of “friend-shoring” in drug manufacturing.

Inside ASCO 2024: Biggest data drops and the best exhibit booth

Cybersecurity lessons from the Change Healthcare hack

Wh itepaper: Top 5 Reasons for Futureproofing Cell Therapy Development

Cell therapy developers face many challenges as they transition from benchtop to bedside. Here we examine when and how to consider transitioning from research-use only to animal free (AF) and GMP critical reagents. Download now.

Resources

Webinar

Enhance your long-term cell & gene therapy success with pDNA manufacturing solutions

Watch our on-demand webinar video to learn more about the challenges in pDNA manufacturing for gene and cell therapy and how to resolve many of these barriers by partnering with our experts through the adoption of vital manufacturing technologies and strategies.

A Comprehensive and Flexible Approach to CMC for Fab and Fc-Fusion Development Programs

New molecular formats are gaining momentum in today’s market. Characterizing these products and developing robust manufacturing processes can help to usher them to market and provide new treatment options for diseases which are currently challenging to treat. Read this white paper to learn more.

Presented by: Lonza

Whitepaper